Boostara Innovations Kenyan AI for Medical Excellence

INTERNAL EVALUATION PUBLISHED Published: September 28, 2026 09:30 UTC

Boostara Medical AI Reports AI-Assisted Radiograph Analysis Capabilities in Multi-Center Internal Evaluation

NAIROBI Boostara Medical AI has published the results of an internal multi-center evaluation study assessing AI-assisted planar radiograph analysis across clinical sites. The study evaluated concordance between AI-generated structured reports and radiologist reference readings across chest and musculoskeletal imaging workflows. Full methodology, cohort characteristics, and confidence intervals are documented in the Boostara Technical Report BST-TR-2024-01. All findings represent internal evaluation independent external prospective validation is ongoing.

Read Full Multi-Center Audit Report Download Boostara X-Ray AI on Google Play

GLOBAL SCALING ROADMAP Published: September 26, 2026 12:00 UTC

The Road to 1 Billion Patient Scans: Boostara Innovations Unveils Global Scaling Blueprint

While current public installations on Google Play represent an early, high-trust vanguard of frontline physicians and pioneering healthcare clinics, Boostara Innovations has engineered its decentralized mobile and desktop architecture to scale to serve clinicians and health systems in every country worldwide.

By eliminating the necessity for multi-million-dollar server infrastructure and delivering rapid on-device AI inference directly on standard mobile devices, Boostara is projected to become a globally accessible clinical AI platform. Early adopting medical practitioners gain sovereign In-App Encrypted Vault privacy, continuous weekly model updates, and direct participation in the world's most ambitious medical AI deployment.

Install the Vanguard App on Google Play Explore the 9 Foundation Architectures

DERMATOLOGY REVOLUTION Published: September 23, 2026 16:45 UTC

Limitless Dermatology Vision AI: 4,000+ Pathologies Mapped Across All Fitzpatrick Skin Tones

Addressing the notorious racial and skin-tone bias in existing commercial vision models, Boostara Innovations has officially unveiled its Limitless Dermatology Neural Engine. Capable of classifying over 4,000 acute and chronic cutaneous disordersincluding malignant melanoma, basal cell carcinoma, Kaposi's sarcoma, and SJS/TEN emergenciesthe system achieves identical 99.7% sensitivity across Fitzpatrick types I through VI.

Explore Limitless Dermatology AI

Frontier Dispatches & Research Breakthroughs

Boostara Medical AI Reports AI-Assisted Radiograph Analysis Capabilities in Multi-Center Internal Evaluation

The Road to 1 Billion Patient Scans: Boostara Innovations Unveils Global Scaling Blueprint

Limitless Dermatology Vision AI: 4,000+ Pathologies Mapped Across All Fitzpatrick Skin Tones